CN116440155A - Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug - Google Patents
Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug Download PDFInfo
- Publication number
- CN116440155A CN116440155A CN202310510657.1A CN202310510657A CN116440155A CN 116440155 A CN116440155 A CN 116440155A CN 202310510657 A CN202310510657 A CN 202310510657A CN 116440155 A CN116440155 A CN 116440155A
- Authority
- CN
- China
- Prior art keywords
- sulfated polysaccharide
- alpha
- coronavirus
- natural sulfated
- marine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 title claims abstract description 80
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 80
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 80
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 201000010099 disease Diseases 0.000 title claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims description 12
- 241000711573 Coronaviridae Species 0.000 claims abstract description 50
- 101800000535 3C-like proteinase Proteins 0.000 claims abstract description 42
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 claims abstract description 42
- 230000000694 effects Effects 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000003112 inhibitor Substances 0.000 claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 17
- 229940096437 Protein S Drugs 0.000 claims abstract description 16
- 101710198474 Spike protein Proteins 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 36
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 36
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 34
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 34
- 101800004803 Papain-like protease Proteins 0.000 claims description 27
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims description 23
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 20
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 17
- 229940097043 glucuronic acid Drugs 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 15
- 241001678559 COVID-19 virus Species 0.000 claims description 14
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 241000711467 Human coronavirus 229E Species 0.000 claims description 5
- 241001109669 Human coronavirus HKU1 Species 0.000 claims description 5
- 241000482741 Human coronavirus NL63 Species 0.000 claims description 5
- 241001428935 Human coronavirus OC43 Species 0.000 claims description 5
- 208000024891 symptom Diseases 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- 241000315672 SARS coronavirus Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 abstract description 2
- 229920000855 Fucoidan Polymers 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 23
- 229920001287 Chondroitin sulfate Polymers 0.000 description 19
- 229940059329 chondroitin sulfate Drugs 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 16
- 150000001875 compounds Chemical class 0.000 description 15
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 14
- 229930182830 galactose Natural products 0.000 description 14
- 150000008267 fucoses Chemical class 0.000 description 13
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 11
- 229920001525 carrageenan Polymers 0.000 description 11
- 241000700605 Viruses Species 0.000 description 10
- 239000000679 carrageenan Substances 0.000 description 10
- 229940113118 carrageenan Drugs 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 229920000669 heparin Polymers 0.000 description 9
- 229960002897 heparin Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- -1 acidic carbohydrates Chemical class 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 5
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 241000251511 Holothuroidea Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 241000199919 Phaeophyceae Species 0.000 description 3
- 241000206572 Rhodophyta Species 0.000 description 3
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 3
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 3
- 239000007984 Tris EDTA buffer Substances 0.000 description 3
- 241000726445 Viroids Species 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000010418 carrageenan Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241001474374 Blennius Species 0.000 description 2
- 241000195628 Chlorophyta Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000010414 supernatant solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101800000504 3C-like protease Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 241001428166 Eucheuma Species 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 101800000596 Probable picornain 3C-like protease Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
The invention belongs to the field of biological medicine, and in particular relates to application of marine organism-derived natural sulfated polysaccharide as a medicine for resisting coronaviruses and diseases caused by coronaviruses. Use of a natural sulfated polysaccharide of marine origin, a pharmaceutically acceptable salt, for the preparation of a medicament for binding to Spike protein (Spike), for the preparation of an inhibitor of main protease (Mpro), or for the preparation of a papain-like (PLpro) inhibitor. The natural sulfated polysaccharide from marine organisms provided by the invention has obvious effect of inhibiting the proliferation of coronaviruses, can inhibit the binding of Spike protein (Spike) on the surface of the coronaviruses and host cells, and can inhibit the activities of main protease (Mpro) and papain-like (PLpro), so that the coronaviruses are effectively blocked from infecting the host cells.
Description
The application is a divisional application of Chinese invention patent application, and the application date of the original application is: 8 months 17 days 2020, application number: 202010825078 . 2, the invention creates the name: application of marine organism source natural sulfated polysaccharide as anti-coronavirus and disease drug, publication No.: CN111773240a; in the process of patent examination, the marine organism source natural sulfated polysaccharide in the original application claim 1 comprises a plurality of parallel technical schemes, and the parallel technical schemes have no specific technical characteristics and have no singleness with each other, so that the divisional application is proposed.
Technical Field
The invention belongs to the field of biological medicine, and in particular relates to application of marine organism-derived natural sulfated polysaccharide as a medicine for resisting coronaviruses and diseases caused by coronaviruses.
Background
The world health organization named the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a novel coronavirus infection (COVID-19) was declared as an international sudden public health event by the world health organization 1 and 30 days 2020. The COVID-19 rapidly spreads worldwide, and presents a great threat to human health and social public health safety. However, no specific medicine for the virus exists at present, and the clinical research and development of anti-SARS-CoV-2 medicine mainly aims at symptomatic treatment for supporting the treatment and improvement of symptoms is indistinct. A number of drug screening experiments have been conducted worldwide for new coronaviruses, but no drug with good therapeutic effect has yet been found.
SARS-CoV-2 is an RNA virus having an envelope structure. The spike glycoprotein on the lipid membrane of the viral particle is responsible for adhesion to the host receptor. Viral genomic RNA within the lipid membrane may encode replicase multimeric proteins that can be cleaved by 3C-like proteases (3 CLpro, also known as the main protease Mpro) and papain-like (PLpro) to produce functional polypeptides, such as RNA-dependent RNA polymerase (RdRp) and helicase (Hel), that are involved in viral RNA transcription and replication. Thus, the spike glycoprotein associated with SARS-CoV-2 infection of host cells, the primary protease associated with SARS-CoV-2 transcriptional replication, and papain-like are important targets for anti-SARS-CoV-2 drug development.
Marine resources are abundant and natural carbohydrates, particularly acidic carbohydrates, derived from marine organisms can bind to proteins that are positively charged by viruses to prevent the viruses from replicating or infecting cells. In addition, the preparation method has the advantages of low toxicity, difficulty in causing virus to generate drug resistance and the like, and has wide prospect in antiviral drug development. Literature searches have found that natural sulfated polysaccharides of marine origin, such as complex structural fucan sulfates of brown algae origin, have an anti-multiple influenza virus effect (publication No. CN 103880975A; patent No. ZL201410132608. X), the backbone structure of which consists of alpha-1, 2-mannose (Man) and beta-1, 4-glucuronic acid (GlcA), contain branched alpha-1, 3-linked-sulfated fucose residues at the mannose C3 position (Jiandong Wu, J Carbohy Chem,34:303-317;Wei Wang,Sci.Rep.2017,7:40760), and that a fucoidan (RPI-27 and RPI-128) of similar structure with different molecular weights (100 kD and 12 kD) has been recently reported to have an activity of inhibiting VID-COV-2 coronavirus Spike protein, which contains alpha-1, 2-mannose (Man) and beta-1, 4-glucuronic acid (GlcA) backbones, and branched alpha-1, 2/3-linked-fucose residues at the mannose C3 position (Cell, 6:50, cup); fucoidan derived from undaria pinnatifida (Hayashi, k., int. Immunopharmacol.2008,8,109) was found to have anti-HSV activity. Studies on other types of structural fucose sulfates against SARS-CoV-2 have not been reported. Carrageenan from red algae has a broad spectrum of anti-H1N 1, HSV, HPV activity (Cui Hao, rev Med Virol.2019, 29, e 2043), and iota-carrageenan also has anti-Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) activity (Chunhe Guo, anti-vir Ther,2019, 24 (4): 261-270), but no anti-neocoronavirus activity has yet been found. Rhamnoglycans sulfate derived from green algae has anti-children hand-foot-mouth virus (EV 71) activity (Shuyao Wan)g, carbohydrate Poly, 2018, 200:43-53) and Newcastle Disease Virus (NDV) Activity (Aguilar-Drugs,2015,13,697-712), but no anti-novel coronavirus activity was found.
Disclosure of Invention
The invention aims to provide an application of marine organism source natural sulfated polysaccharide in preparing medicines for resisting coronaviruses and diseases caused by the coronaviruses, and provides an effective medicine for treating coronaviruses, especially novel coronavirus pneumonia (COVID-19) and a composition thereof, wherein specific marine plants and marine animals are taken as raw materials, serial marine source natural sulfated polysaccharides are obtained through extraction and separation, and the activity of the marine organism source natural sulfated polysaccharide in inhibiting coronaviruses, especially novel coronaviruses (SARS-COV-2) is screened.
The technical scheme of the invention is as follows:
an application of marine organism source natural sulfated polysaccharide in preparing medicament for resisting coronavirus and diseases caused by coronavirus, an application of marine organism source natural sulfated polysaccharide and pharmaceutically acceptable salt in preparing medicament for combining with Spike protein (Spike), preparing inhibitor of main protease (Mpro) or preparing papain-like (PLpro) inhibitor, wherein the marine organism source natural sulfated polysaccharide has any one of the following structural characteristics, and the molecular weight range is 3-600 kDa, and the application comprises the following steps:
(1) Fucoidan sulfate (also known as fucoidan) has one of the following structural features: (a) Fucoidan of type I structure, the backbone consisting of α -1, 3-linked sulfated fucose; (b) Fucoidin with a II type structure, wherein the main chain consists of sulfated fucose with alpha-1, 3 and alpha-1, 4 alternately connected; (c) Fucoidin with III structure, wherein the main chain consists of beta-1, 4-glucuronic acid and alpha-1, 2-mannose, and the branch structure consists of alpha-1, 3-sulfated fucoidin; (d) Other types of fucoidan, the backbone consisting of α -1,2 and α -1,3 and/or α -1,4 linked sulfated fucose;
(2) Fucosylated chondroitin sulfate, its structural features are as follows: chondroitin sulfate disaccharide repeating units with main chains formed by alternately connecting glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) through beta-1, 3 and beta-1, 4 glycosidic bonds, wherein hydroxyl groups at C4, C6 or C4 and C6 of GalNAc contain sulfate groups, and sulfated fucooligosaccharide branches are connected at C3 position of GlcA through alpha-1, 3 glycosidic bonds;
(3) The structural characteristics of the sulfated galactan are as follows: galactose (Gal) consisting of a beta-1, 3-linkage and an alpha-1, 4-linkage, or a galactose (AnG) consisting of a beta-1, 3-linkage and an alpha-1, 4-linkage-3, 6-endo-ether, and having different sulfate groups at the C2, C4 or C6 positions of the galactose;
(4) Rhamnoglycan sulfate: the structural characteristics are as follows: is formed by alternately connecting rhamnose (Rha) and glucuronic acid through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively connecting Rha and iduronic acid via alpha-1, 4 glycosidic bond; or alternatively connecting rhamnose (Rha) and xylose (Xyl) through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively, the alpha-1, 2 and the alpha-1, 3-rhamnose are connected alternately; and the C2 and/or C3 position of the structural Rha contains sulfate ester groups.
The fucoidin with the I-type structure also has other sugar residue branched chain structures; in the type II structural fucoidan, other sugar residue branched chain structures are also provided.
The coronavirus is one or more than two selected from SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV.
The natural sulfated polysaccharide is derived from marine plants or marine animals.
The natural sulfated polysaccharide can be used as an inhibitor for inhibiting the infection cells of coronaviruses by combining with Spike protein (Spike) of the coronaviruses, and can inhibit the replication and amplification of the viruses by inhibiting the activity of main protease (Mpro) and/or papain-like protease (PLpro) of the coronaviruses.
The application of the natural sulfated polysaccharide and the pharmaceutically acceptable salt in preparing coronavirus inhibitors.
The application of the natural sulfated polysaccharide and the pharmaceutically acceptable salt in preparing medicaments for preventing and/or treating coronavirus infection or preventing and/or treating diseases or symptoms related to coronavirus infection.
The application of the natural sulfated polysaccharide, a kit or a reagent for combining pharmaceutically acceptable salts and Spike protein (Spike), a kit or a reagent for preparing a main protease (Mpro) inhibitor, or a kit or a reagent for preparing a papain-like protease (PLpro) inhibitor.
The natural sulfated polysaccharide, the pharmaceutically acceptable salt and one or more than two other active agents for preventing and/or treating coronavirus infection are mixed to prepare a pharmaceutical composition for preventing and/or treating coronavirus infection.
The design idea of the invention is as follows:
the natural sulfated polysaccharide from marine organisms provided by the invention can inhibit the binding of Spike protein (Spike) on the surface of coronaviruses and host cells, so that the coronaviruses are effectively blocked from infecting the host cells, and the activities of main protease (Mpro) and papain-like protease (PLpro) of the coronaviruses can be inhibited, so that the replication and amplification processes of the viruses are inhibited. Therefore, the marine natural sulfated polysaccharide provided by the invention has great potential for developing anti-coronavirus and disease-causing drugs.
The invention has the advantages and beneficial effects that:
(1) The natural sulfated polysaccharide from marine organisms provided by the invention can inhibit Spike protein (Spike) on the surface of coronaviruses from being combined with host cells, and the inhibition activity level of the natural sulfated polysaccharide is superior to that of clinical drugs heparin and low-molecular heparin.
(2) The natural sulfated polysaccharide from marine organisms provided by the invention has the activity of inhibiting main protease (Mpro) and papain-like protease (PLpro), and the inhibition activity level is superior to that of heparin.
(3) In the whole, the anti-coronavirus activity and the better than clinical drugs heparin and low molecular heparin of the natural sulfated polysaccharide derived from marine organisms can be used in the preparation and application fields of anti-coronavirus and related diseases.
Drawings
FIG. 1 inhibitory activity of fucan sulfate, galactan sulfate, fucosylated chondroitin sulfate, rhamno sulfate, and heparin on SARS-CoV-2 spike protein. In the figure, the abscissa Log Dose represents the logarithm of the compound concentration (. Mu.M), and the ordinate Relative Luminescence represents the relative luminous intensity (%).
FIG. 2 inhibition curves of the SARS-CoV-2 main protease by galactan sulfate, fucan sulfate, fucosylated chondroitin sulfate. In the figure, the abscissa Time represents Time(s), the ordinate Intensity represents fluorescence Intensity, blank represents Blank, iota-carageenan represents Iota-carrageenan, FCS represents fucosylated chondroitin sulfate, and Fucoidan represents Fucoidan sulfate.
FIG. 3 inhibition of SARS-CoV-2 main protease IC by fucan sulfate 50 The curve is determined. In the figure, log concentration on the abscissa represents Log concentration (nM), IC 50 Representing half the inhibitory concentration.
Detailed Description
In a specific implementation process, the invention relates to application of marine-source natural sulfated polysaccharide and pharmaceutically acceptable salt in preparation of coronavirus inhibition inhibitor, wherein the natural sulfated polysaccharide has any one of the following structures:
(1) Fucoidan sulfate (also known as fucoidan), comprising: (a) Type I fucoidin, the main chain of which consists of alpha-1, 3-linked sulfated fucoidin, and can also have other sugar residue branched chain structures; (b) Type II fucoidin, the main chain is composed of sulfated fucoidin with alpha-1, 3 and alpha-1, 4 alternately connected, and can also have other sugar residue branched chain structure; (c) Type III fucoidin, wherein the main chain consists of beta-1, 4-glucuronic acid and alpha-1, 2-mannose, and the branch structure consists of alpha-1, 3-sulfated fucoidin; (d) Other types of fucoidan have a backbone consisting of alpha-1, 2 and alpha-1, 3 and/or alpha-1, 4 linked sulfated fucose.
(2) Fucosylated chondroitin sulfate, its structural features are as follows: chondroitin sulfate disaccharide repeating units with main chains formed by alternately connecting glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) through beta-1, 3 and beta-1, 4 glycosidic bonds, and sulfated fuco-oligosaccharide branched chains are connected at the C3 position of GlcA through alpha-1, 3 glycosidic bonds.
(3) The structural characteristics of the sulfated galactan are as follows: galactose (Gal) consisting of beta-1, 3-linkage and alpha-1, 4-linkage, or galactose (AnG) consisting of beta-1, 3-linkage and alpha-1, 4-linkage-3, 6-endo-ether, and having different sulfate groups at the C2, C4 or C6 positions of galactose.
(4) The rhamnoglycan sulfate is characterized by comprising the following structural characteristics: is formed by alternately connecting rhamnose (Rha) and glucuronic acid through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively connecting Rha and iduronic acid via alpha-1, 4 glycosidic bond; or alternatively connecting rhamnose (Rha) and xylose (Xyl) through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively, the alpha-1, 2 and the alpha-1, 3-rhamnose are connected alternately; and the C2 and/or C3 position of the structural Rha contains sulfate ester groups.
The invention also provides the use of a marine organism-derived natural sulfated polysaccharide having any of the following structures, a pharmaceutically acceptable salt thereof, for the preparation of a medicament for binding to Spike protein (Spike), for the preparation of a main protease (Mpro) inhibitor, or for the preparation of a papain-like protease (PLpro) inhibitor:
(1) Fucoidan sulfate (also known as fucoidan), comprising: (a) Fucoidan of type I structure, the main chain of which consists of alpha-1, 3-linked sulfated fucose, can also have branched chain structure of other sugar residues; (b) Fucoidan with II type structure, wherein the main chain consists of sulfated fucose with alternately connected alpha-1, 3 and alpha-1, 4, and can also have branched chain structure of other sugar residues; (c) Fucoidin with a III type structure, wherein the main chain consists of beta-1, 4-glucuronic acid and alpha-1, 2-mannose, and the branch structure consists of alpha-1, 3-sulfated fucoidin; (d) Other types of fucoidan have a backbone consisting of alpha-1, 2 and alpha-1, 3 and/or alpha-1, 4 linked sulfated fucose.
(2) Fucosylated chondroitin sulfate, its structural features are as follows: chondroitin sulfate disaccharide repeating units with main chains formed by alternately connecting glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) through beta-1, 3 and beta-1, 4 glycosidic bonds, and sulfated fucose branches are connected at the C3 position of GlcA through alpha-1, 3 glycosidic bonds.
(3) The structural characteristics of the sulfated galactan are as follows: galactose (Gal) consisting of beta-1, 3-linkage and alpha-1, 4-linkage, or galactose (AnG) consisting of beta-1, 3-linkage and alpha-1, 4-linkage-3, 6-endo-ether, and having different sulfate groups at the C2, C4 or C6 positions of galactose.
(4) Rhamnoglycan sulfate: the structural characteristics are as follows: is formed by alternately connecting rhamnose (Rha) and glucuronic acid through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively connected by Rha and iduronic acid (IdoA) through alpha-1, 4 glycosidic bond; or alternatively connecting rhamnose (Rha) and xylose (Xyl) through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively, the alpha-1, 2 and the alpha-1, 3-rhamnose are connected alternately; and the C2 and/or C3 position of the structural Rha contains sulfate ester groups.
For the above-described applications, it is preferable that one or two or more of Spike protein (Spike), main protease (Mpro), papain-like protease (PLpro) in coronavirus; more preferably, the coronavirus is selected from one or more of the group consisting of COVID-19 (SARS-CoV-2), HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV.
The invention also provides application of the marine organism source natural sulfated polysaccharide and pharmaceutically acceptable salt in preparation of coronavirus inhibitor.
The invention also provides application of the marine organism-derived natural sulfated polysaccharide and pharmaceutically acceptable salt in preparing medicaments for preventing and/or treating coronavirus infection or preventing and/or treating diseases or symptoms related to coronavirus infection.
For use as described above, preferably the coronavirus is selected from the group consisting of COVID-19 (SARS-CoV-2), HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV.
The invention also provides application of the marine organism-derived natural sulfated polysaccharide and pharmaceutically acceptable salt in preparing a kit or reagent for binding with Spike protein (Spike), a kit or reagent for preparing a main protease (Mpro) inhibitor, or a kit or reagent for preparing a papain-like protease (PLpro) inhibitor.
The invention also provides a pharmaceutical composition for preventing and/or treating coronavirus infection, which comprises the marine organism-derived natural sulfated polysaccharide, pharmaceutically acceptable salt and one or more than two other active agents for preventing and/or treating coronavirus infection.
Preferably, the molecular weight of the marine organism-derived natural sulfated polysaccharide as described above ranges from 3 to 600kDa.
The experimental screening research shows that the natural sulfated polysaccharides from marine organisms have better inhibition effect on coronaviruses, especially Spike protein (Spike) of novel coronavirus (SARS-CoV-2), main protease (Mpro or 3CL pro) and PLpro. The invention provides the application potential of marine organism source natural sulfated polysaccharide in resisting coronavirus, especially SARS-CoV-2, and proves that the marine organism source natural sulfated polysaccharide has good clinical development and application prospect.
The marine organism source natural sulfated polysaccharide provided by the invention is preferably characterized by comprising the following structural characteristics:
(1) Fucoidan sulfate (also known as fucoidan), comprising: (a) Fucoidan of type I structure, the main chain of which consists of alpha-1, 3-linked sulfated fucose, can also have branched chain structure of other sugar residues; (b) Fucoidan with II type structure, wherein the main chain consists of sulfated fucose with alternately connected alpha-1, 3 and alpha-1, 4, and can also have branched chain structure of other sugar residues; (c) Fucoidin with a III type structure, wherein the main chain consists of beta-1, 4-glucuronic acid and alpha-1, 2-mannose, and the branch structure consists of alpha-1, 3-sulfated fucoidin; (d) Other types of fucoidan have a backbone consisting of alpha-1, 2 and alpha-1, 3 and/or alpha-1, 4 linked sulfated fucose.
(2) Fucosylated chondroitin sulfate, its structural features are as follows: chondroitin sulfate disaccharide repeating units with main chains formed by alternately connecting glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) through beta-1, 3 and beta-1, 4 glycosidic bonds, and sulfated fucose branches are connected at the C3 position of GlcA through alpha-1, 3 glycosidic bonds.
(3) The structural characteristics of the sulfated galactan are as follows: consists of beta-1, 3-linked and alpha-1, 4-linked galactose (Gal), or of beta-1, 3-linked galactose and alpha-1, 4-linked-3, 6-endo-ether galactose (AnG), with the C2, C4 or C6 position of galactose containing different sulphate groups.
(4) Rhamnoglycan sulfate: the structural characteristics are as follows: is formed by alternately connecting rhamnose (Rha) and glucuronic acid through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively connecting Rha and iduronic acid via alpha-1, 4 glycosidic bond; or alternatively connecting rhamnose (Rha) and xylose (Xyl) through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively, the alpha-1, 2 and the alpha-1, 3-rhamnose are connected alternately; and the C2 and/or C3 position of the structural Rha contains sulfate ester groups.
The marine organism-derived sulfated polysaccharides of the invention have the effect of inhibiting coronaviruses, in particular novel coronaviruses (SARS-CoV-2). Experimental results show that the sulfated polysaccharides from various marine organisms provided by the invention have remarkable anti-novel coronavirus effect and inhibit Spike IC 50 IC with value between 0.01 and 30 mu M for inhibiting Mpro 50 IC with a value between 1nM and 100nM for inhibiting papain-like protease (PLpro) 50 The value is 0.001-30 mu M. IC for inhibiting Mpro by fucoidan 50 IC that inhibits Spike protein at 5.68nM 50 IC inhibiting papain-like protease (PLpro) at 0.06. Mu.M 50 7.65nM, and the effect is significantly better than heparin.
As a preferred embodiment, the use as described above, the coronaviruses include, but are not limited to, novel coronaviruses (COVID-19), HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV (causing severe acute respiratory syndrome) and MERS-CoV (causing middle east respiratory syndrome).
The application of the marine organism source natural sulfated polysaccharide in resisting novel coronaviruses can prepare the marine organism source natural sulfated polysaccharide into spray, injection, capsule, ointment, cream, gel, liniment.
The therapeutically effective amount of the marine organism-derived natural sulfated polysaccharide, pharmaceutically acceptable salt, or stereoisomer of the invention is preferably administered to a patient in need of such treatment in accordance with the usual route of administration and formulated according to methods known in the art in conventional pharmaceutical compositions comprising an effective amount of the active ingredient and a suitable pharmaceutically acceptable carrier and dosage form.
By "therapeutically effective amount" is meant an amount which, when administered, is sufficient to prevent the development of, or to alleviate to some extent, one or more symptoms of the disease for which it is intended. The specific dosage of the compounds administered according to the present invention will be determined by the specific circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and similar considerations. In particular, a "therapeutically effective amount" of a compound refers to an amount of the compound that is sufficient to prevent or to some extent ameliorate one or more coronavirus infections.
The individual doses and daily doses will further vary depending on the type and severity of the coronavirus infection to be treated and the response of the particular patient to the drug treatment. Thus, an accurate single dose will be determined according to standard medical principles under the direction of a physician.
The human effective daily dosage of the marine-derived natural sulfated polysaccharide, pharmaceutically acceptable salt of the invention for use in treating coronavirus-derived diseases is 1mg to about 500mg, about 5mg to about 1000mg, or about 10mg to about 2000mg of an injectable or other active agent oral dosage form.
The marine-derived natural sulfated polysaccharides and pharmaceutically acceptable salts of the present invention may be used alone or in combination with other therapeutic agents.
In one embodiment of the invention, the marine-derived natural sulfated polysaccharide, pharmaceutically acceptable salt, is for use in the prevention and/or treatment of coronavirus infection, wherein the prevention or treatment comprises administration as the sole active ingredient.
In another embodiment of the invention, the marine organism-derived natural sulfated polysaccharide, pharmaceutically acceptable salt described above, is for use in the prevention and/or treatment of coronavirus infection, wherein the prevention or treatment comprises use in combination therapy with a therapeutic agent selected from the group consisting of other therapeutic agents.
As will be apparent to those skilled in the art, the combination of the present invention comprising a marine-derived natural sulfated polysaccharide of the present invention, a pharmaceutically acceptable salt, and an additional therapeutic agent is effective not only when these active ingredients are used in a single composition, but also when they are used in two different compositions (administered simultaneously, sequentially, or separately after a period of time). Furthermore, it will be appreciated by those skilled in the art that the marine-derived natural sulfated polysaccharides, pharmaceutically acceptable salts of the present invention may be formulated for use with other active ingredients in combination therapies to prevent and/or treat coronavirus infections.
In a particular embodiment, the combination therapy comprises administering to a subject the marine organism-derived natural sulfated polysaccharide of the invention, a pharmaceutically acceptable salt, and an additional therapeutic agent, simultaneously, sequentially, or separately. Alternatively, the combination therapy comprises administering to a subject the marine organism-derived natural sulfated polysaccharide of the invention, a pharmaceutically acceptable salt or stereoisomer, and an additional therapeutic agent in a single composition.
In one embodiment of the present invention, the marine-derived natural sulfated polysaccharide, pharmaceutically acceptable salt, or stereoisomer of the present invention may be conveniently administered to a patient. Thus, the compounds for use in the present invention may be in the form of a pharmaceutical composition comprising an effective amount of the marine-derived natural sulfated polysaccharide of the invention, a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable excipient or carrier. This aspect may also be expressed as a composition comprising an effective amount of a marine organism-derived natural sulfated polysaccharide, a pharmaceutically acceptable salt of the invention in combination with a pharmaceutically acceptable excipient or carrier for use in the prevention and/or treatment of coronavirus infection.
In one embodiment of the invention, the compounds used may be administered orally, by injection, subcutaneously, respiratory tract, transdermally, parenterally, rectally, topically, intravenously, intramuscularly or by other means in a dosage unit formulation comprising conventional pharmaceutical carriers. The pharmaceutical composition may be formulated in any pharmaceutically acceptable form, such as: tablets, granules, injections, gels, pills, capsules, suppositories, implants, nano-preparations and powder injections. Some dosage forms, such as tablets and capsules, may be subdivided into suitable dosage unit forms containing an appropriate amount of the active component, such as an amount effective to achieve the desired end.
In another embodiment, the marine-derived natural sulfated polysaccharide, pharmaceutically acceptable salt for use in the present invention is an injectable formulation to be administered to a patient to be treated, and the injectable formulation suitable for use in the present invention refers to a sterilized or sterile solution, emulsion or suspension of a drug with a suitable solvent or dispersion medium for injection into a human body, and a powder sterile formulation for formulation into a solution or suspension prior to use. The injection includes injection (where large volume injection for intravenous drip is also called intravenous infusion), sterile powder for injection and concentrated solution for injection.
The carrier includes excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient to be treated. The carrier may be inert or it may have a pharmaceutical benefit itself.
The types of carriers include, but are not limited to: diluents such as fillers and bulking agents, binders, lubricants, anti-caking agents, disintegrants, sweeteners, buffers, preservatives, solubilizers, isotonic agents, suspending and dispersing agents, wetting or emulsifying agents, flavoring and perfuming agents, thickening agents and vehicles.
Alternative active agents may be included in the pharmaceutical compositions that do not substantially affect the activity of the compounds of the present invention.
The invention is further illustrated in the following drawings and specific examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art. Reagents and materials used in the following examples are commercially available unless otherwise specified. The marine organism source natural sulfated polysaccharide has the following structure:
(1) Fucoidan sulfate: the backbone consisted of alpha-1, 3-linked sulfated fucose with a molecular weight of 600kDa.
(2) Iota-carrageenan: consists of a beta-1, 3-linked galactose and alpha-1, 4-linked-3, 6-lacto-galactose repeating disaccharide unit, the C4 position of galactose residue and the C2 position of lacto-galactose residue are replaced by sulfate radical, and the molecular weight is 200kDa.
(3) Fucosylated chondroitin sulfate: chondroitin sulfate disaccharide repeating units with main chains formed by alternately connecting glucuronic acid (GlcA) and N-acetylgalactosamine (GalNAc) through beta-1, 3 and beta-1, 4 glycosidic bonds, and fucose branched chains with C2 and C3 replaced by sulfate radicals at C3 position of GlcA through alpha-1, 3 glycosidic bonds, wherein the molecular weight is 3kDa and 50kDa.
(4) Rhamnoglycan sulfate: is formed by alternately connecting rhamnose (Rha) and glucuronic acid through alpha-1, 4 and beta-1, 4 glycosidic bonds, wherein the C2 and C3 positions of the Rha contain sulfate groups; the molecular weight is 200kDa.
Example-inhibition of SARS-CoV-2 spike protein by marine-derived Natural sulfated polysaccharide
Based on the SARS-CoV-2-spike protein virus detection system, the effect of fucoidan (derived from brown algae), iota-carrageenan (derived from red algae), fucosylated chondroitin sulfate (derived from sea cucumber) and rhamnosan sulfate (derived from green algae) on blocking SARS-CoV-2 infected cells was evaluated.
The sulfated polysaccharide samples employed in the present invention may be extracted using reagents, methods and apparatus conventional in the art.
1) Cell resuscitating culture: the 293T/17 human embryo kidney cell strain is cultured by mixing 10% fetal calf serum, 1% diabody and the balance of DMEM culture medium according to weight percentage, and the cells are cultured for two generations after resuscitating for later use.
2) Viroid preparation: 293T/17 human embryonic kidney cells were plated into 6-well cell culture plates, when cell confluency reached about 60%, 3. Mu.g of the plasmid was subjected to pack transfection with a transfection reagent (Lipofiter 3.0), and then the 6-well cell culture plates were placed in a carbon dioxide incubator (37 ℃,5% CO) 2 ) Culturing, collecting viroid supernatant solution after 48h transfection, and preserving at-80 ℃.
3) Transient transfection of cells: 293T/17 human embryonic kidney cells were plated into 6-well cell culture plates, and when cell confluency reached about 70%, 3. Mu.g of plasmid (ACE 2-pcDNA3.1) was transfected into 293T17 cells using a transfection reagent (lipofilter 3.0), and the 6-well cell culture plates were incubated in a carbon dioxide incubator for 48h.
4) Cell digestion: the transiently transfected 293T/17 human embryonic kidney cells are digested by pancreatin, resuspended in complete medium, counted by a cell counter, plated on 96-well cell culture plates with 12000 cells per well, and cultured for 6-8 h.
5) Preparation of natural sulfated polysaccharides from marine organisms with different concentrations: the compound to be tested was prepared as a stock solution with a molar concentration of 1mM, and according to the difference in the concentration detected on the cell line, 9 dilutions with different concentration gradients were prepared in the molar concentration range of 0.00015 to 1.00mM, and stored in 1.5mL clear EP tubes, respectively, at-20 ℃. The prepared 9 concentration gradient compounds to be tested are respectively diluted by 10 times by using a complete culture medium, and simultaneously, the same volume of dimethyl sulfoxide (DMSO) solvent is used as a control.
6) And (3) paving: taking out 96-well white cell culture plate adhered with wall for 6-8 hr in incubator, taking out 60 μl of each well, adding 10 μl of the test substance into the culture plate containing 40 μl of cell volume, each concentration gradient of 2 multiple wells, and culturing in incubator (37deg.C, 5% CO) 2 ) After 1 hour of medium culture, 50 mu L of collected viroid supernatant solution is added into each hole, wherein the final detection concentration of the compound to be detected is 9 concentration gradients with the molar concentration range of 0.00152-10.00 mu M; after the plates were placed in an incubator for 24 hours of incubation, 100. Mu.L of medium was replaced for further incubation for 48 hours and detection.
7) Reading a plate: renilla luciferase detection reagent was allowed to stand at room temperature, the cell culture plate was removed and allowed to stand for 10 minutes to equilibrate to room temperature, 15. Mu.L of detection reagent was added to each well, the plate was shaken on an orbital shaker for 2 minutes to induce cell lysis, the plate was allowed to stand at room temperature for 10 minutes, and the luminescence signal was measured on an MD (Molecular Devices, mei Gu molecule) SpectraMax Paradigm plate reader.
8) Data analysis: using SpectraMax Paradigm readings, the corresponding fluorescence per well values RLU were obtained. The data is processed using the following formula: RLU (%) = (RLU) Drug )/(RLU DMSO ) 100%. The cell viability was calculated in EXCEL for the different concentrations of compound, and then plotted using GraphPad 7.0Prism software to calculate eachIC of compound 50 Values. The results are shown in the following table,
| compounds of formula (I) | IC 50 (μM) |
| Heparin | 10.0 |
| Fucoidan sulfate | 0.06 |
| iota-carrageenan | 0.27 |
| Fucosylated chondroitin sulfate | 0.25 |
| Rhamnoglycans sulfate | 0.44 |
As shown in figure 1, the series of marine organism source natural sulfated polysaccharides have obvious inhibition effect on blocking new coronavirus (SARS-CoV-2) infected cells, and the effect of the compounds fucoidan sulfate, carrageenan, fucosylated chondroitin sulfate, rhamnoides sulfate and other marine organism source natural sulfated polysaccharides on blocking virus infected cells is stronger than that of Heparin (Heparin).
EXAMPLE two inhibition of SARS-CoV-2 Main protease by marine-derived Natural sulfated polysaccharide
SARS-CoV-2 main protease can hydrolyze the fluorescent polypeptide substrate to cause the substrate to fluoresce. The activity of the main protease is inhibited by marine natural sulfated polysaccharide, and the fluorescence intensity is reduced compared with that of a blank control. Among them, the main protease and the fluorescent polypeptide substrate can be obtained by the report method of document W.Dai et al, science 10.1126/Science. Abb4489 (2020).
(1) TE buffer solution preparation
100. Mu.L of an aqueous solution of disodium ethylenediamine tetraacetate (EDTA-2 Na) having a molar concentration of 0.5M was added to 2.5mL of a 1M Tris-HCl buffer, the volume was adjusted to 50mL, and the solution was filtered through a filter membrane having a pH of 7.3,0.22. Mu.m, followed by storage at-4 ℃.
(2) Screening of main protease inhibition activity by marine organism-derived sulfated polysaccharide
Adding 87 mu L TE buffer solution into 96-well cell culture plate, adding 1 mu L main protease with molar concentration of 19.7 mu M respectively, mixing well, and adding H 2 O (2. Mu.L), seaweed-derived fucoidan sulfate aqueous solution (2. Mu.L, molar concentration 15. Mu.M; molecular weight 260.1 kDa), eucheuma-derived iota-carrageenan (2. Mu.L, molar concentration 15. Mu.M; molecular weight 200 kDa), shark-derived keratan sulfate (2. Mu.L, molar concentration 15. Mu.M, molecular weight 45.98 kDa) and sea cucumber-derived fucosylated chondroitin sulfate (2. Mu.L, molar concentration 15. Mu.M, molecular weight 42 kDa) were sequentially and respectively added to each well, shaking was carried out, and after 30min of reaction at room temperature, 10. Mu.L of a substrate having a molar concentration of 20. Mu.M was added to each well, and fluorescence intensity was rapidly detected by an enzyme-labeling instrument. The sulfated polysaccharide samples employed in the present invention may be extracted using reagents, methods and apparatus conventional in the art.
(3) Detection condition of enzyme-labeled instrument
Continuously detecting the fluorescence intensity of each hole within 10min under the conditions of the excitation wavelength of 320nm, the emission wavelength of 405nm and the detection temperature of 27 ℃ to obtain a time-fluorescence intensity dynamic curve.
(4) Data processing
Performing linear fitting based on the obtained time-fluorescence intensity dynamic curve to obtain the slope k of the corresponding curve of the natural sulfated polysaccharides from each ocean source and the slope k of the corresponding curve of the blank control 0
Inhibition of the main protease by the naturally sulfated polysaccharide (molar concentration 300 nM) = (1-k/k) 0 )×100％
| Compounds of formula (I) | Inhibition/% |
| Heparin | 72.2 |
| Fucoidan sulfate | 92.3 |
| iota-carrageenan | 62.8 |
| Fucosylated chondroitin sulfate | 65.9 |
| Rhamnoglycans sulfate | 75.0 |
As shown in figure 2, the inhibition rate of brown algae source fucoidan sulfate, red algae source carrageenan and sea cucumber source fucosylated chondroitin sulfate on SARS-CoV-2 main protease activity is all higher than 50%.
EXAMPLE three inhibition of SARS-CoV-2 Main protease by fucoidan at different concentrations
(1) Inhibition experiment of fucoidan on Main protease Activity
Adding 87 μL TE buffer solution into 96-well cell culture plate, adding 1 μL main protease with molar concentration of 19.7 μM, mixing, and adding 2 μLH respectively 2 O and 9 fucoidan sulfate aqueous solutions of seaweed origin with a molar concentration range of 0.5nM to 45. Mu.M in concentration gradients are added in sequence to eachThe wells were shaken well and reacted at room temperature for 30min, and then 10. Mu.L of substrate with a molar concentration of 20. Mu.M was added to each well, followed by rapid detection of fluorescence intensity using an ELISA reader. The sulfated polysaccharide samples employed in the present invention may be extracted using reagents, methods and apparatus conventional in the art.
(2) Detection condition of enzyme-labeled instrument
Continuously detecting the fluorescence intensity of each hole within 10min under the conditions of the excitation wavelength of 320nm, the emission wavelength of 405nm and the detection temperature of 27 ℃ to obtain a time-fluorescence intensity dynamic curve.
(3) Data processing
Performing linear fitting based on the obtained time-fluorescence intensity dynamic curve to obtain the slope k of the corresponding curve of the fucoidan sulfate and the slope k of the corresponding curve of the blank control under different concentrations 0
Inhibition rate of fucoidan to main protease by different concentrations= (1-k/k) 0 )×100％
(4)IC 50 Calculation of
The IC was obtained by plotting the logarithm of the concentration against the inhibition rate using the software origin 8.1 and by using a nonlinear fit 50 Values.
(5) Results
As shown in FIG. 3, marine-derived fucoidan has good inhibitory effect on the activity of main protease, and its corresponding IC 50 Value = 5.68 ± 0.43nM (nmol/L)
Experimental results show that the marine organism-derived natural sulfated polysaccharide provided by the invention has obvious effect of inhibiting the proliferation of coronaviruses, can inhibit the binding of Spike protein (Spike) on the surface of coronaviruses and host cells, and can inhibit the activities of main protease (Mpro) and papain-like (PLpro), so that the infection of coronaviruses to host cells is effectively blocked.
Claims (8)
1. The application of marine organism source natural sulfated polysaccharide as coronavirus and disease-resistant drug is characterized in that the application of marine organism source natural sulfated polysaccharide and pharmaceutically acceptable salt in preparing drugs combined with Spike protein (Spike), preparing inhibitors of main protease (Mpro) or preparing papain-like (PLpro) inhibitors is characterized in that the marine organism source natural sulfated polysaccharide is rhamnosan, and the marine organism source natural sulfated polysaccharide is characterized in that: is formed by alternately connecting rhamnose (Rha) and glucuronic acid through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively connecting Rha and iduronic acid via alpha-1, 4 glycosidic bond; or alternatively connecting rhamnose (Rha) and xylose (Xyl) through alpha-1, 4 and beta-1, 4 glycosidic bonds; or alternatively, the alpha-1, 2 and the alpha-1, 3-rhamnose are connected alternately; and the C2 and/or C3 position of the structural Rha contains sulfate groups, and the molecular weight of the structural Rha ranges from 3kDa to 600kDa.
2. The use according to claim 1, wherein the coronavirus is selected from one or more of SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, SARS-CoV and MERS-CoV.
3. The use according to claim 1, wherein the naturally sulfated polysaccharide is derived from a marine plant or a marine animal.
4. Use according to claim 1, wherein the natural sulfated polysaccharide, by binding to Spike protein (Spike) of coronavirus, acts as an inhibitor of its invading cells, inhibiting viral replication and amplification by inhibiting coronavirus main protease (Mpro) and/or papain-like protease (PLpro) activity.
5. The use according to claim 1, wherein the natural sulfated polysaccharide, pharmaceutically acceptable salt is used in the preparation of coronavirus inhibitors.
6. The use according to claim 1, wherein the natural sulfated polysaccharide, pharmaceutically acceptable salt is used for the preparation of a medicament for preventing and/or treating coronavirus infection, or for preventing and/or treating diseases or symptoms associated with coronavirus infection.
7. The use according to claim 1, wherein the natural sulfated polysaccharide, the pharmaceutically acceptable salt, and the Spike protein (Spike) are combined in a kit or reagent, a kit or reagent for preparing a main protease (Mpro) inhibitor, or a kit or reagent for preparing a papain-like protease (PLpro) inhibitor.
8. The use according to claim 1, wherein the natural sulfated polysaccharide, the pharmaceutically acceptable salt, and the additional one or more than two agents for preventing and/or treating coronavirus infection are mixed to prepare a pharmaceutical composition for preventing and/or treating coronavirus infection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310510657.1A CN116440155B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010825078.2A CN111773240B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
| CN202310510657.1A CN116440155B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010825078.2A Division CN111773240B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116440155A true CN116440155A (en) | 2023-07-18 |
| CN116440155B CN116440155B (en) | 2024-03-29 |
Family
ID=72762729
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010825078.2A Active CN111773240B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
| CN202310510655.2A Pending CN116392503A (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
| CN202310510657.1A Active CN116440155B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
| CN202310510656.7A Pending CN116392504A (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010825078.2A Active CN111773240B (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
| CN202310510655.2A Pending CN116392503A (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310510656.7A Pending CN116392504A (en) | 2020-08-17 | 2020-08-17 | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (4) | CN111773240B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112220799A (en) * | 2020-11-02 | 2021-01-15 | 江苏泰德医药有限公司 | Product for inhibiting virus and application |
| CN113181207B (en) * | 2021-02-06 | 2023-06-27 | 中国海洋大学 | Use of oligomannuronate phosphate for the preparation of a medicament for the prevention and treatment of novel coronavirus infections |
| US20240189375A1 (en) * | 2021-04-13 | 2024-06-13 | Philip Morris Products S.A. | Composition comprising a eukaryotic microalgae or an extract thereof for use in the treatment of a viral disease |
| CN113150178B (en) * | 2021-04-14 | 2023-05-02 | 大连工业大学 | Sulfated abalone polysaccharide and application thereof in inhibiting new coronavirus |
| CN114097832A (en) * | 2021-11-30 | 2022-03-01 | 常德集智生物科技有限公司 | Long-acting inactivated virus spray and preparation method thereof |
| CN114316081B (en) * | 2021-12-07 | 2023-03-28 | 大连工业大学 | A sulfated polysaccharide of Botrytis longipedicularis with SARS-CoV-2 inhibiting activity, and its preparation method and application |
| CN114732827B (en) * | 2022-06-10 | 2022-09-27 | 中国海洋大学 | Application of sulfated polysaccharides from different marine organisms and pharmaceutical composition thereof |
| CN117883468A (en) * | 2022-10-14 | 2024-04-16 | 华东理工大学 | New coronavirus resistant application of sulfonated polysaccharide |
| CN118085116A (en) * | 2024-01-16 | 2024-05-28 | 中欣安德森(广东)生物技术有限公司 | Use of laminarin for antivirus and sterilizing |
-
2020
- 2020-08-17 CN CN202010825078.2A patent/CN111773240B/en active Active
- 2020-08-17 CN CN202310510655.2A patent/CN116392503A/en active Pending
- 2020-08-17 CN CN202310510657.1A patent/CN116440155B/en active Active
- 2020-08-17 CN CN202310510656.7A patent/CN116392504A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| MASAHIRO TERASAWA等: "Anti-Influenza A Virus Activity of Rhamnan Sulfate from Green Algae Monostroma nitidum in Mice with Normal and Compromised Immunity", 《MARINE DRUGS》, vol. 18, no. 254, pages 1 - 13 * |
| PAUL S. KWON等: "Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro", 《CELL DISCOVERY》, vol. 6, no. 50, pages 1 - 4 * |
| 客观日本: "最新发现！海藻"石莼"能抑制人类冠状病毒繁殖，期待对新冠病毒也有效", pages 1 - 3, Retrieved from the Internet <URL:《https://mp.weixin.qq.com/s?src=11×tamp=1704680128&ver=5005&signature=TEoa5fMLSSfUgFoccB9VgOScgJmsn200HBcpRLC4KwsVWxN1ccF8x*ML7GFc7qtbu1zcOisghMZ5tXHqo2kcjQ7RP*wrfwnxtO036dKngxQIGbWqPyCk5HoPjWRBvmsJ&new=1》> * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111773240A (en) | 2020-10-16 |
| CN111773240B (en) | 2023-06-16 |
| CN116392503A (en) | 2023-07-07 |
| CN116392504A (en) | 2023-07-07 |
| CN116440155B (en) | 2024-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116440155B (en) | Application of marine organism-derived natural sulfated polysaccharide as anti-coronavirus and disease-causing drug | |
| CN106727623B (en) | Application of seaweed oligosaccharide in preparation of anti-avian leukosis virus preparation | |
| CN116634883A (en) | Method for producing pharmaceutical preparations | |
| CN114053297B (en) | Application of alginic acid derivative in resisting coronavirus and diseases caused by alginic acid derivative | |
| CN112022845A (en) | Application of quercetin in preparation of novel anti-coronavirus drugs | |
| CN114748466B (en) | Application of Napyradiomycin compounds in preparation of porcine pseudorabies virus inhibitor | |
| CN112022867B (en) | Application of geraniin in preparing anti-novel coronary virus medicine | |
| CN112691117A (en) | New use of heparin sodium for infection of novel coronavirus SARS-CoV-2 | |
| CN111358774A (en) | Astaxanthin and adriamycin combined preparation and application thereof | |
| RU2752872C1 (en) | SARS-CoV-2 CORONAVIRUS REPLICATION INHIBITOR BASED ON HUMIC SUBSTANCES | |
| CN115137762B (en) | Cyclocarya paliurus extract and application thereof in preparation of anti-coronavirus drugs | |
| CN118286196B (en) | Application of salvianolic acid A in preparation of anti-bovine nodular skin disease virus drugs | |
| CN115671126A (en) | Application of didanosine in inhibition of echinococcosis hepatica | |
| CN115068452B (en) | Application of aloe-emodin in preparing medicine for preventing and treating African swine fever | |
| CN117379544B (en) | Antibody composition and application thereof in preparation of anti-new coronavirus drugs | |
| JPH0454125A (en) | Drug for treating and preventing disease infected with retrovirus | |
| CN1279953A (en) | Application of seeweed polyose sulphate | |
| CN114504589A (en) | Application of gambogic acid and decitabine in preparation of anti-T cell lymphoma drugs | |
| CN115671095A (en) | Application of mycophenolic acid in inhibiting echinococcosis hepatica | |
| CN116115606A (en) | Application of Xanthoxol in preparing medicament for treating cisplatin-induced acute kidney injury | |
| DE69529070T2 (en) | USE OF 5,6-O-BENZYLIDEN-L-ASCORBIC ACID OR ITS SALTS FOR PRODUCING A MEDICINE FOR TREATING HIV | |
| CN112569250A (en) | Application of trifluridine in preparing HIV-1 medicine | |
| CN118806782A (en) | Application of baicalein combined with gemcitabine in preparation of medicines for resisting porcine epidemic diarrhea virus | |
| CN100430412C (en) | Nucleic acid molecule RTN4BSR6 and application for preparation of anti-cancer drugs | |
| CN117323361A (en) | Pharmaceutical composition for treating brain glioma and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |